Figure 5

Verbascoside (VB) promoted apoptosis via p53 in human CRC cells. CRC HCT-116 and HT-29 cells were treated by VB at indicated doses and duration, and then analyzed for apoptosis by flow cytometry. Inhibition at 25, 50, and 100 μM of VB to HCT-116 cells was 20.20 ± 4.08%, 43.28 ± 9.80%, and 56.79 ± 9.11% (A), and HT-29 cells, 4.36 ± 3.39%, 18.22 ± 3.94%, and 37.01 ± 6.98%, respectively (B). HCT-116 apoptosis rate after being treated with 25, 50, and 100 μM of VB was 10.83 ± 1.28%, 11.25 ± 1.54%, and 20.19 ± 2.8%, and the HT-29 apoptosis rate, 18.92 ± 6.12%, 21.57 ± 4.05%, and 25.14 ± 6.73%, respectively (C). HCT-116 and HT-29 apoptosis rate was 11.25 ± 1.54% and 21.57 ± 4.05% after being treated with 50 μM Verbascoside; and 5.03 ± 2.77% and 3.11 ± 1.16% after being treated with FPT-a (p53-specific inhibitor); and 5.02 ± 0.73% and 3.18 ± 1.82% after being treated with FPT-a and 50 μM VB respectively (D).